期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 122, 期 -, 页码 339-351出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2016.06.010
关键词
PI3 kinase; Kinase selectivity; Platelet aggregation inhibitors; Thrombosis
资金
- National Health and Medical Research Council of Australia (NHMRC) [1093062, 545943]
- National Health and Medical Research Council of Australia [1093062] Funding Source: NHMRC
A series of amino-substituted triazines were developed and examined for PI3K13 inhibition and anti platelet function. Structural adaptations of a morpholine ring of the prototype pan-PI3K inhibitor ZSTK474 yielded PI3K beta selective compounds, where the selectivity largely derives from an interaction with the non-conserved Asp862 residue, as shown by site directed mutagenesis. The most PI3K beta selective inhibitor from the series was studied in detail through a series of in vitro and in vivo functional studies. MIPS-9922, 10 potently inhibited ADP-induced washed platelet aggregation. It also inhibited integrin alpha(IIb)beta(3) activation and alpha(IIb)beta(3) dependent platelet adhesion to immobilized vWF under high shear. It prevented arterial thrombus formation in the in vivo electrolytic mouse model of thrombosis without inducing prolonged bleeding or excess blood loss. (C) 2016 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据